Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 524 entries
Sorted by: Best Match Show Resources per page
Epitope targeting with self-assembled peptide vaccines.

NPJ vaccines

Zeigler DF, Gage E, Roque R, Clegg CH.
PMID: 31341647
NPJ Vaccines. 2019 Jul 19;4:30. doi: 10.1038/s41541-019-0125-5. eCollection 2019.

Nanoparticle-based delivery systems are being used to simplify and accelerate new vaccine development. Previously, we described the solid-phase synthesis of a 61-amino acid conjugate vaccine carrier comprising a α-helical domain followed by two universal T cell epitopes. Circular dichroism,...

Cite
Zeigler DF, Gage E, Roque R, et al. Epitope targeting with self-assembled peptide vaccines. NPJ Vaccines. 2019;4:30doi: 10.1038/s41541-019-0125-5.
Zeigler, D. F., Gage, E., Roque, R., & Clegg, C. H. (2019). Epitope targeting with self-assembled peptide vaccines. NPJ vaccines, 430. https://doi.org/10.1038/s41541-019-0125-5
Zeigler, David F, et al. "Epitope targeting with self-assembled peptide vaccines." NPJ vaccines vol. 4 (2019): 30. doi: https://doi.org/10.1038/s41541-019-0125-5
Zeigler DF, Gage E, Roque R, Clegg CH. Epitope targeting with self-assembled peptide vaccines. NPJ Vaccines. 2019 Jul 19;4:30. doi: 10.1038/s41541-019-0125-5. eCollection 2019. PMID: 31341647; PMCID: PMC6642127.
Copy Download .nbib Format: NLM
A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains.

NPJ vaccines

Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P.
PMID: 31341648
NPJ Vaccines. 2019 Jul 19;4:31. doi: 10.1038/s41541-019-0126-4. eCollection 2019.

Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to...

Cite
Broecker F, Liu STH, Suntronwong N, et al. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines. 2019;4:31doi: 10.1038/s41541-019-0126-4.
Broecker, F., Liu, S. T. H., Suntronwong, N., Sun, W., Bailey, M. J., Nachbagauer, R., Krammer, F., & Palese, P. (2019). A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ vaccines, 431. https://doi.org/10.1038/s41541-019-0126-4
Broecker, Felix, et al. "A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains." NPJ vaccines vol. 4 (2019): 31. doi: https://doi.org/10.1038/s41541-019-0126-4
Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines. 2019 Jul 19;4:31. doi: 10.1038/s41541-019-0126-4. eCollection 2019. PMID: 31341648; PMCID: PMC6642189.
Copy Download .nbib Format: NLM
An Ad/MVA vectored .

NPJ vaccines

Svitek N, Saya R, Awino E, Munyao S, Muriuki R, Njoroge T, Pellé R, Ndiwa N, Poole J, Gilbert S, Nene V, Steinaa L.
PMID: 30245859
NPJ Vaccines. 2018 Sep 11;3:35. doi: 10.1038/s41541-018-0073-5. eCollection 2018.

The parasite

Cite
Svitek N, Saya R, Awino E, et al. An Ad/MVA vectored . NPJ Vaccines. 2018;3:35doi: 10.1038/s41541-018-0073-5.
Svitek, N., Saya, R., Awino, E., Munyao, S., Muriuki, R., Njoroge, T., Pellé, R., Ndiwa, N., Poole, J., Gilbert, S., Nene, V., & Steinaa, L. (2018). An Ad/MVA vectored . NPJ vaccines, 335. https://doi.org/10.1038/s41541-018-0073-5
Svitek, Nicholas, et al. "An Ad/MVA vectored ." NPJ vaccines vol. 3 (2018): 35. doi: https://doi.org/10.1038/s41541-018-0073-5
Svitek N, Saya R, Awino E, Munyao S, Muriuki R, Njoroge T, Pellé R, Ndiwa N, Poole J, Gilbert S, Nene V, Steinaa L. An Ad/MVA vectored . NPJ Vaccines. 2018 Sep 11;3:35. doi: 10.1038/s41541-018-0073-5. eCollection 2018. PMID: 30245859; PMCID: PMC6134044.
Copy Download .nbib Format: NLM
Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.

NPJ vaccines

Rhodes SJ, Guedj J, Fletcher HA, Lindenstrøm T, Scriba TJ, Evans TG, Knight GM, White RG.
PMID: 30245860
NPJ Vaccines. 2018 Sep 17;3:36. doi: 10.1038/s41541-018-0075-3. eCollection 2018.

Unlike drug dose optimisation, mathematical modelling has not been applied to vaccine dose finding. We applied a novel Immunostimulation/Immunodynamic mathematical modelling framework to translate multi-dose TB vaccine immune responses from mice, to predict most immunogenic dose in humans. Data...

Cite
Rhodes SJ, Guedj J, Fletcher HA, et al. Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. NPJ Vaccines. 2018;3:36doi: 10.1038/s41541-018-0075-3.
Rhodes, S. J., Guedj, J., Fletcher, H. A., Lindenstrøm, T., Scriba, T. J., Evans, T. G., Knight, G. M., & White, R. G. (2018). Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. NPJ vaccines, 336. https://doi.org/10.1038/s41541-018-0075-3
Rhodes, Sophie J, et al. "Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making." NPJ vaccines vol. 3 (2018): 36. doi: https://doi.org/10.1038/s41541-018-0075-3
Rhodes SJ, Guedj J, Fletcher HA, Lindenstrøm T, Scriba TJ, Evans TG, Knight GM, White RG. Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. NPJ Vaccines. 2018 Sep 17;3:36. doi: 10.1038/s41541-018-0075-3. eCollection 2018. PMID: 30245860; PMCID: PMC6141590.
Copy Download .nbib Format: NLM
A malaria vaccine protects .

NPJ vaccines

Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, Lugo-Roman L, Lucas C, Orr-Gonzalez S, Zhu D, Villasante E, Soisson L, Narum DL, Pierce SK, Long CA, Diggs C, Duffy PE, Lescano AG, Miller LH.
PMID: 28804644
NPJ Vaccines. 2017;2. doi: 10.1038/s41541-017-0015-7. Epub 2017 May 22.

The

Cite
Srinivasan P, Baldeviano GC, Miura K, et al. A malaria vaccine protects . NPJ Vaccines. 2017;2doi: 10.1038/s41541-017-0015-7.
Srinivasan, P., Baldeviano, G. C., Miura, K., Diouf, A., Ventocilla, J. A., Leiva, K. P., Lugo-Roman, L., Lucas, C., Orr-Gonzalez, S., Zhu, D., Villasante, E., Soisson, L., Narum, D. L., Pierce, S. K., Long, C. A., Diggs, C., Duffy, P. E., Lescano, A. G., & Miller, L. H. (2017). A malaria vaccine protects . NPJ vaccines, 2. https://doi.org/10.1038/s41541-017-0015-7
Srinivasan, Prakash, et al. "A malaria vaccine protects ." NPJ vaccines vol. 2 (2017). doi: https://doi.org/10.1038/s41541-017-0015-7
Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, Lugo-Roman L, Lucas C, Orr-Gonzalez S, Zhu D, Villasante E, Soisson L, Narum DL, Pierce SK, Long CA, Diggs C, Duffy PE, Lescano AG, Miller LH. A malaria vaccine protects . NPJ Vaccines. 2017;2. doi: 10.1038/s41541-017-0015-7. Epub 2017 May 22. PMID: 28804644; PMCID: PMC5551459.
Copy Download .nbib Format: NLM
A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.

NPJ vaccines

Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Albrecht RA, Krammer F.
PMID: 29263881
NPJ Vaccines. 2017 Sep 14;2:26. doi: 10.1038/s41541-017-0026-4. eCollection 2017.

Influenza viruses evade human adaptive immune responses due to continuing antigenic changes. This makes it necessary to re-formulate and re-administer current seasonal influenza vaccines on an annual basis. Our pan-influenza vaccination approach attempts to redirect antibody responses from the...

Cite
Nachbagauer R, Liu WC, Choi A, et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines. 2017;2:26doi: 10.1038/s41541-017-0026-4.
Nachbagauer, R., Liu, W. C., Choi, A., Wohlbold, T. J., Atlas, T., Rajendran, M., Solórzano, A., Berlanda-Scorza, F., García-Sastre, A., Palese, P., Albrecht, R. A., & Krammer, F. (2017). A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ vaccines, 226. https://doi.org/10.1038/s41541-017-0026-4
Nachbagauer, Raffael, et al. "A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies." NPJ vaccines vol. 2 (2017): 26. doi: https://doi.org/10.1038/s41541-017-0026-4
Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Albrecht RA, Krammer F. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines. 2017 Sep 14;2:26. doi: 10.1038/s41541-017-0026-4. eCollection 2017. PMID: 29263881; PMCID: PMC5627297.
Copy Download .nbib Format: NLM
Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.

NPJ vaccines

Li F, Freed DC, Tang A, Rustandi RR, Troutman MC, Espeseth AS, Zhang N, An Z, McVoy M, Zhu H, Ha S, Wang D, Adler SP, Fu TM.
PMID: 29263890
NPJ Vaccines. 2017 Dec 14;2:36. doi: 10.1038/s41541-017-0038-0. eCollection 2017.

Human cytomegalovirus (HCMV) is the leading cause of in utero viral infection in the United States. Since congenital HCMV infection can lead to birth defects in newborns, developing a prophylactic vaccine is a high priority. One of the early...

Cite
Li F, Freed DC, Tang A, et al. Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination. NPJ Vaccines. 2017;2:36doi: 10.1038/s41541-017-0038-0.
Li, F., Freed, D. C., Tang, A., Rustandi, R. R., Troutman, M. C., Espeseth, A. S., Zhang, N., An, Z., McVoy, M., Zhu, H., Ha, S., Wang, D., Adler, S. P., & Fu, T. M. (2017). Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination. NPJ vaccines, 236. https://doi.org/10.1038/s41541-017-0038-0
Li, Fengsheng, et al. "Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination." NPJ vaccines vol. 2 (2017): 36. doi: https://doi.org/10.1038/s41541-017-0038-0
Li F, Freed DC, Tang A, Rustandi RR, Troutman MC, Espeseth AS, Zhang N, An Z, McVoy M, Zhu H, Ha S, Wang D, Adler SP, Fu TM. Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination. NPJ Vaccines. 2017 Dec 14;2:36. doi: 10.1038/s41541-017-0038-0. eCollection 2017. PMID: 29263890; PMCID: PMC5730571.
Copy Download .nbib Format: NLM
From therapeutic antibodies to immune complex vaccines.

NPJ vaccines

Wang XY, Wang B, Wen YM.
PMID: 30675393
NPJ Vaccines. 2019 Jan 17;4:2. doi: 10.1038/s41541-018-0095-z. eCollection 2019.

In recent years, therapeutic monoclonal antibodies have made impressive progress, providing great benefit by successfully treating malignant and chronic inflammatory diseases. Monoclonal antibodies with broadly neutralizing effects against specific antigens, or that target specific immune regulators, manifest therapeutic effects...

Cite
Wang XY, Wang B, Wen YM. From therapeutic antibodies to immune complex vaccines. NPJ Vaccines. 2019;4:2doi: 10.1038/s41541-018-0095-z.
Wang, X. Y., Wang, B., & Wen, Y. M. (2019). From therapeutic antibodies to immune complex vaccines. NPJ vaccines, 42. https://doi.org/10.1038/s41541-018-0095-z
Wang, Xuan-Yi, et al. "From therapeutic antibodies to immune complex vaccines." NPJ vaccines vol. 4 (2019): 2. doi: https://doi.org/10.1038/s41541-018-0095-z
Wang XY, Wang B, Wen YM. From therapeutic antibodies to immune complex vaccines. NPJ Vaccines. 2019 Jan 17;4:2. doi: 10.1038/s41541-018-0095-z. eCollection 2019. PMID: 30675393; PMCID: PMC6336872.
Copy Download .nbib Format: NLM
Protection against inhalation anthrax by immunization with .

NPJ vaccines

Sim BKL, Li M, Osorio M, Wu Y, Wai TT, Peterson JW, James ER, Chakravarty S, Gao L, Xu R, Kc N, Stafford RE, Lawrence WS, Yeager LA, Peel JE, Sivasubramani SK, Chopra AK, Filippova S, Hoffman SL.
PMID: 29263873
NPJ Vaccines. 2017 Jun 15;2:17. doi: 10.1038/s41541-017-0018-4. eCollection 2017.

The national blueprint for biodefense concluded that the United States is underprepared for biological threats. The licensed anthrax vaccine absorbed vaccine, BioThrax, requires administration of at least 3-5 intramuscular doses. The anthrax vaccine absorbed vaccine consists of complex cell-free...

Cite
Sim BKL, Li M, Osorio M, et al. Protection against inhalation anthrax by immunization with . NPJ Vaccines. 2017;2:17doi: 10.1038/s41541-017-0018-4.
Sim, B. K. L., Li, M., Osorio, M., Wu, Y., Wai, T. T., Peterson, J. W., James, E. R., Chakravarty, S., Gao, L., Xu, R., Kc, N., Stafford, R. E., Lawrence, W. S., Yeager, L. A., Peel, J. E., Sivasubramani, S. K., Chopra, A. K., Filippova, S., & Hoffman, S. L. (2017). Protection against inhalation anthrax by immunization with . NPJ vaccines, 217. https://doi.org/10.1038/s41541-017-0018-4
Sim, B Kim Lee, et al. "Protection against inhalation anthrax by immunization with ." NPJ vaccines vol. 2 (2017): 17. doi: https://doi.org/10.1038/s41541-017-0018-4
Sim BKL, Li M, Osorio M, Wu Y, Wai TT, Peterson JW, James ER, Chakravarty S, Gao L, Xu R, Kc N, Stafford RE, Lawrence WS, Yeager LA, Peel JE, Sivasubramani SK, Chopra AK, Filippova S, Hoffman SL. Protection against inhalation anthrax by immunization with . NPJ Vaccines. 2017 Jun 15;2:17. doi: 10.1038/s41541-017-0018-4. eCollection 2017. PMID: 29263873; PMCID: PMC5627300.
Copy Download .nbib Format: NLM
A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

NPJ vaccines

Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG.
PMID: 29263878
NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.

Vaccine development for vector-borne pathogens may be accelerated through the use of relevant challenge models, as has been the case for malaria. Because of the demonstrated biological importance of vector-derived molecules in establishing natural infections, incorporating natural challenge models...

Cite
Duthie MS, Pereira L, Favila M, et al. A defined subunit vaccine that protects against vector-borne visceral leishmaniasis. NPJ Vaccines. 2017;2:23doi: 10.1038/s41541-017-0025-5.
Duthie, M. S., Pereira, L., Favila, M., Hofmeyer, K. A., Reed, S. J., Metangmo, S., Townsend, S., Laurance, J. D., Picone, A., Misquith, A., Hossain, F., Ghosh, P., Khan, M. A. A., Guderian, J., Bailor, H. R., Liang, H., Vergara, J., Oliveira, F., Howard, R. F., Kamhawi, S., Mondal, D., Coler, R. N., Valenzuela, J. G., & Reed, S. G. (2017). A defined subunit vaccine that protects against vector-borne visceral leishmaniasis. NPJ vaccines, 223. https://doi.org/10.1038/s41541-017-0025-5
Duthie, Malcolm S, et al. "A defined subunit vaccine that protects against vector-borne visceral leishmaniasis." NPJ vaccines vol. 2 (2017): 23. doi: https://doi.org/10.1038/s41541-017-0025-5
Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG. A defined subunit vaccine that protects against vector-borne visceral leishmaniasis. NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017. PMID: 29263878; PMCID: PMC5627294.
Copy Download .nbib Format: NLM
Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells.

NPJ vaccines

Park HY, Tan PS, Kavishna R, Ker A, Lu J, Chan CEZ, Hanson BJ, MacAry PA, Caminschi I, Shortman K, Alonso S, Lahoud MH.
PMID: 29263886
NPJ Vaccines. 2017 Nov 06;2:31. doi: 10.1038/s41541-017-0033-5. eCollection 2017.

Targeting model antigens (Ags) to Clec9A on DC has been shown to induce, not only cytotoxic T cells, but also high levels of Ab. In fact, Ab responses against immunogenic Ag were effectively generated even in the absence of...

Cite
Park HY, Tan PS, Kavishna R, et al. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells. NPJ Vaccines. 2017;2:31doi: 10.1038/s41541-017-0033-5.
Park, H. Y., Tan, P. S., Kavishna, R., Ker, A., Lu, J., Chan, C. E. Z., Hanson, B. J., MacAry, P. A., Caminschi, I., Shortman, K., Alonso, S., & Lahoud, M. H. (2017). Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells. NPJ vaccines, 231. https://doi.org/10.1038/s41541-017-0033-5
Park, Hae-Young, et al. "Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells." NPJ vaccines vol. 2 (2017): 31. doi: https://doi.org/10.1038/s41541-017-0033-5
Park HY, Tan PS, Kavishna R, Ker A, Lu J, Chan CEZ, Hanson BJ, MacAry PA, Caminschi I, Shortman K, Alonso S, Lahoud MH. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells. NPJ Vaccines. 2017 Nov 06;2:31. doi: 10.1038/s41541-017-0033-5. eCollection 2017. PMID: 29263886; PMCID: PMC5674066.
Copy Download .nbib Format: NLM
Plague vaccine: recent progress and prospects.

NPJ vaccines

Sun W, Singh AK.
PMID: 30792905
NPJ Vaccines. 2019 Feb 18;4:11. doi: 10.1038/s41541-019-0105-9. eCollection 2019.

Three great plague pandemics, resulting in nearly 200 million deaths in human history and usage as a biowarfare agent, have made

Cite
Sun W, Singh AK. Plague vaccine: recent progress and prospects. NPJ Vaccines. 2019;4:11doi: 10.1038/s41541-019-0105-9.
Sun, W., & Singh, A. K. (2019). Plague vaccine: recent progress and prospects. NPJ vaccines, 411. https://doi.org/10.1038/s41541-019-0105-9
Sun, Wei, and Singh, Amit K. "Plague vaccine: recent progress and prospects." NPJ vaccines vol. 4 (2019): 11. doi: https://doi.org/10.1038/s41541-019-0105-9
Sun W, Singh AK. Plague vaccine: recent progress and prospects. NPJ Vaccines. 2019 Feb 18;4:11. doi: 10.1038/s41541-019-0105-9. eCollection 2019. PMID: 30792905; PMCID: PMC6379378.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 524 entries